Secondary Logo

Journal Logo

AAPA Members can view Full text articles for FREE. Not a Member? Join today!

Institutional members access full text with Ovid®

What is the role of PCSK9 inhibitors in treating hypercholesterolemia?

Volpe, Mark, MPH, MMSc, PA-C

Journal of the American Academy of PAs: June 2018 - Volume 31 - Issue 6 - p 14–15
doi: 10.1097/01.JAA.0000532126.38283.02
Pharmacology Consult

ABSTRACT PCSK9 inhibitors are a novel medical therapy for treating hypercholesterolemia. This article reviews the basic properties of PCSK9 inhibitors, including their mechanism of action, indications, contraindications, adverse reactions, and efficacy.

Mark Volpe practices at Suffield (Conn.) Medical Associates, New England Urgent Care in Enfield, Conn., and Priority Urgent Care in Ellington, Conn. He is a guest lecturer in the University of St. Joseph PA program in West Hartford, Conn., and a clinical preceptor for students in the PA program at Yale University in New Haven, Conn. The author has disclosed no potential conflicts of interest, financial or otherwise.

Mary Lou Brubaker, PharmD, PA-C, department editor

Copyright © 2018 American Academy of Physician Assistants
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website